Research stack

Tesamorelin Heavy-Training GH Axis Support

Continuous GHRH analog dosing during a strength or hypertrophy block.

Component peptides

A stabilised GHRH analog carrying a trans-3-hexenoyl group at the N-terminus, protecting against dipeptidyl-peptidase-IV cleavage. FDA-approved in 2010 as Egrifta for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Goal

Continuous GHRH-analog dosing during a strength or hypertrophy block.

Peptides

Tesamorelin

Why it works

The stabilized GHRH analog restores pulsatile endogenous GH secretion, providing somatotropic support with a pulsatile pattern rather than sustained GH elevation.

How to use

Tesamorelin — 2 mg once daily subcutaneous, evening.

Last updated: 2026-09-15

Component peptides	Tesamorelin
Duration reported	26 weeks
Cycle pattern	Continuous, 26 weeks per pivotal protocol
Difficulty	intermediate
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.